Beijing Jushu Biotechnology
Synthetic biology platform for intelligent cell design
About Beijing Jushu Biotechnology
Beijing Jushu Biotechnology is a data-driven synthetic biology company founded in 2021. The firm operates a biotechnology engineering platform that leverages genome editing, high-throughput droplet microfluidics, and data science to intelligently design and engineer microbial and mammalian cells. This platform aims to accelerate the development and optimization of cell chassis for various industrial applications.
The company's core technology integrates CRISPR-based genome-wide editing with ultra-high-throughput droplet microfluidic screening. This allows for the rapid analysis of genotype-phenotype associations across the entire genome, enabling the discovery of novel genetic targets for cell engineering. By combining wet lab automation with deep learning and metabolic network modeling, Jushu Biotech has created a data-mechanism hybrid-driven platform for the customized design and construction of engineered cells. One of its key projects includes the development of next-generation CHO (Chinese Hamster Ovary) cell lines to overcome domestic bottlenecks in biopharmaceutical production.
Jushu Biotech's business model is product-driven, focusing on the research, development, and industrialization of products for sectors including healthcare, bio-based chemicals and materials, agricultural technology, and future foods. The company generates revenue through its own product lines and by establishing technology development and industrial partnerships with other companies and research institutions. Since its inception, the company has secured multiple rounds of venture capital funding, including a Series A round in April 2024 with investors such as Zhongsu Capital and Guolian Group.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 17.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Nov 2023 | $14M | $55M | Chengwei Capital · Shanghai Zhongsu Venture Capital Management · Binhu State Investment · 3E Bioventures | ↗ |
| ANGELEquity / VC | Jan 2023 | $1.2M | $4.8M | Chengwei Capital · Empower Investment | ↗ |
Growth signals
Latest recorded traffic for Beijing Jushu Biotechnology is 410 monthly website visits, down 10.9% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Jushu Biotechnology in its local ecosystem
The Beijing Jushu Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Chengwei Capital- EIEmpower Investment
- SMShanghai Zhongsu Venture Capital Management
- BIBinhu State Investment
3E Bioventures
Wuxi Innovation Investment Group
Other known investors1 additional known investor
Tsinghua University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Jushu Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Jushu Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









